Streetwise Reports' Article Archives — October 2020 back to current month (26)
Acadia Healthcare Shares Rise 20% on Q3 Earnings and Positive Forward Guidance (10/30/2020)
Shares of Acadia Healthcare reached a new 52-week high after the company reported Q3/20 financial results that included a 7.5% YoY increase in revenue at its U.S. health facilities.
Biotech Expects Interim Analysis Data from Phase 3 COVID-19 Study by Year-End (10/28/2020)
Revive Therapeutics anticipates that more than 200 patients will complete its Phase 3 clinical trial of Bucillamine in patients with mild-moderate COVID-19 by the end of December 2020 and stated that those results will help identify the best dosage levels for the rest of the trial.
Exact Sciences Shares Rise 29% as Firm Announces Q3 Earnings, a Capital Raise and Two Acquisitions (10/27/2020)
Exact Sciences Corp. shares reached a new 52-week high after the maker of cancer screening test Cologuard reported Q3/20 financial results that included a greater than 86% increase in year-over-year revenue.
Mirati Therapeutics' Shares Rise 12.5% on Positive Data from Cancer Studies (10/26/2020)
Mirati Therapeutics' shares reached a new 52-week high after the company reported preliminary data for Adagrasib (MRTX849) demonstrated durable anti-tumor activity in its non-small cell lung cancer and colorectal cancer studies.
Biopharma White Paper Posits FDA Approval of Biogen's Alzheimer's Drug Likely Next Month (10/23/2020)
ProMIS Neurosciences cites "unequivocally positive data" and encouraging FDA actions with respect to the therapeutic.
Align Technology Shares Head Straight Up on 20.9% Q3 Revenue Growth as Firm Celebrates its 9 Millionth Invisalign Patient (10/22/2020)
Shares of Align Technology traded 35% higher and climbed to a new 52-week high after the company reported Q3/20 financial results that included a 20.9% YoY increase in net revenues.
Biotech Secures Supplier of Psilocybin, Other Psychedelics (10/21/2020)
Revive Therapeutics will use these products in future studies and clinical trials.
Aptinyx Shares Trade 17% Higher on Positive Top-Line Data in Phase 2 PTSD Trial (10/20/2020)
Aptinyx shares set a new 52-week high price after the company reported statistically significant, top-line data from its Phase 2 Study of NYX-783 in patients diagnosed with post-traumatic stress disorder.
BioSpecifics Technologies Agrees to $658 Million Buyout Offer from Endo Pharmaceuticals (10/19/2020)
Biospecifics Technologies shares traded 45% higher after the company reported that it agreed to be acquired by Endo Pharmaceuticals for $88.50 per share in an all cash transaction.
With Bases Loaded, NervGen Swings for the Fences in Traumatic Brain Injury (10/19/2020)
Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co.
Organogenesis Shares Rise 20% on Q3 Net Revenue Growth and FY Guidance (10/15/2020)
Shares of Organogenesis Holdings traded higher after the company reported preliminary Q3/20 financial results demonstrating a 55% increase in year-over-year revenue.
Biopharma Announces Pulmonary Fibrosis Trial Now 25% Enrolled (10/14/2020)
Five sites in Australia and New Zealand are participating in this study of Algernon Pharmaceuticals' drug.
Life Sciences Firm Lands Record 4 Metric Tons Order for Antibiotic-Free Feedstock (10/14/2020)
Avivagen Inc. reported that it has received a record purchase order for its OxC-beta™ product from UNAHCO.
Phase 3 COVID-19 Study of Firm's Stem Cell Product Exceeds 50% Enrollment (10/14/2020)
The study design and goals and Mesoblast's next steps are reviewed in a Dawson James Securities report.
Allscripts Agrees to Sell Its CarePort Health Business for $1.35 Billion (10/14/2020)
Shares of Allscripts Healthcare Solutions traded 30% higher after the company reported it has agreed to sell its CarePort Health business to WellSky Corp. for $1.35 billion.
Altimmune Publishes Compelling Preclinical Data for Intranasal COVID-19 Vaccine Candidate (10/13/2020)
Altimmune Inc. shares traded 12% higher after the company published preclinical studies conducted together with the University of Alabama at Birmingham for AdCOVID, its intranasal COVID-19 vaccine candidate.
CareDx Shares Trade Up 15% After Announcing 57% YoY Increase in Q3 Revenue (10/08/2020)
CareDx shares established a new 52-week high after the company reported that preliminary revenue in Q3/20 increased 57% year-over-year to $53.0 million.
StreetSmart Live! Presents Algernon Pharmaceuticals (10/08/2020)
Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events.
Immunotherapy Firm Announces Positive Top-Line Trial Results for Severe and Critical COVID-19 Patients (10/07/2020)
The study data and potential near-term catalysts for Enlivex Therapeutics are covered in an H.C. Wainwright & Co. report.
Creator of Antibiotic-Free Livestock Supplement Extends Reach in Mexico (10/07/2020)
Avivagen reports that it has gained both new customers and increased access to prospective ones.
Ocular Therapeutix Shares Rise 25% After Firm Reports 250% Sequential Increase in Q3 Revenue (10/07/2020)
Ocular Therapeutix shares reached a new 52-week high after the company reported that preliminary net product revenue increased to $5.8-5.9 million during Q3/20, representing a more than 250% increase over the previous quarter.
Biopharma's Multinational COVID-19 Study Hits 75% Enrollment Mark (10/05/2020)
Algernon Pharmaceuticals expects completion of the clinical trial next month and data readout by year-end.
MyoKardia Shares Don't Skip a Beat on $13.1 Billion Acquisition by Bristol Myers Squibb (10/05/2020)
Shares of MyoKardia traded 58% higher after the company reported that Bristol Myers Squibb has agreed to acquire the firm for $13.1 billion, or $225.00 per share in cash.
American Renal Associates Agrees to Private Equity Firm's $853 Million Buyout Offer (10/02/2020)
Shares of American Renal Associates traded 67% higher and set a new 52-week high after the company reported that it has entered into a definitive agreement to be acquired by a Nautic Partners LLC affiliate for $11.50 per share in cash.
CloudMD: The Best Bet in Telehealth? (10/01/2020)
Peter Epstein of Epstein Research reviews the reasons he believes CloudMD is poised for substantial growth compared to peers.
AMAG Pharma Receives $647 Million Takeover Bid from Luxembourg Firm (10/01/2020)
Shares of AMAG Pharmaceuticals traded 44% higher after the company reported it has agreed to be acquired by Covis Group S.à r.l. for $13.75 per share in cash, or approximately $498 million on a fully diluted basis.
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec